CA 58236/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
1993	1
1994	4
1995	9
1996	12
1997	9
1998	10
1999	11
2000	7
2001	6
2002	8
2003	8
2004	6
2005	4
2007	1
2008	1
2009	3
2021	0

1

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Hu R, et al. Cancer Res. 2009 Jan 1;69(1):16-22. doi: 10.1158/0008-5472.CAN-08-2764. Cancer Res. 2009. PMID: 19117982 Free PMC article.

2

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Zhong H, et al. Cancer Res. 1999 Nov 15;59(22):5830-5. Cancer Res. 1999. PMID: 10582706 Free article.

3

HIF at the crossroads between ischemia and carcinogenesis.

Paul SA, Simons JW, Mabjeesh NJ. Paul SA, et al. J Cell Physiol. 2004 Jul;200(1):20-30. doi: 10.1002/jcp.10479. J Cell Physiol. 2004. PMID: 15137054 Review.

4

Genetic alterations in prostate cancer.

Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Isaacs WB, et al. Cold Spring Harb Symp Quant Biol. 1994;59:653-9. doi: 10.1101/sqb.1994.059.01.075. Cold Spring Harb Symp Quant Biol. 1994. PMID: 7587126 Review.

5

Gene therapy of prostate cancer: current and future directions.

Mabjeesh NJ, Zhong H, Simons JW. Mabjeesh NJ, et al. Endocr Relat Cancer. 2002 Jun;9(2):115-39. doi: 10.1677/erc.0.0090115. Endocr Relat Cancer. 2002. PMID: 12121835 Review.

6

Androgen-receptor gene structure and function in prostate cancer.

Hakimi JM, Rondinelli RH, Schoenberg MP, Barrack ER. Hakimi JM, et al. World J Urol. 1996;14(5):329-37. doi: 10.1007/BF00184606. World J Urol. 1996. PMID: 8912473 Review.

7

Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.

Jimeno A, Carducci M. Jimeno A, et al. Expert Rev Anticancer Ther. 2005 Jun;5(3):419-27. doi: 10.1586/14737140.5.3.419. Expert Rev Anticancer Ther. 2005. PMID: 16001950 Review.

8

Stem cell features of benign and malignant prostate epithelial cells.

De Marzo AM, Nelson WG, Meeker AK, Coffey DS. De Marzo AM, et al. J Urol. 1998 Dec;160(6 Pt 2):2381-92. doi: 10.1097/00005392-199812020-00004. J Urol. 1998. PMID: 9817389 Review.

9

Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells.

Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Rinker-Schaeffer CW, et al. Prostate. 1994 Nov;25(5):249-65. doi: 10.1002/pros.2990250505. Prostate. 1994. PMID: 7971516 Review.

10

Molecular biology of prostate cancer progression.

Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Isaacs WB, et al. Cancer Surv. 1995;23:19-32. Cancer Surv. 1995. PMID: 7621457 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results